Rare Case: New Atrial Fibrillation After Starting Tirzepatide
A 62-year-old woman with no prior heart disease developed new-onset atrial fibrillation shortly after starting tirzepatide, requiring intensive care.
Quick Facts
What This Study Found
New-onset atrial fibrillation requiring intensive care occurred in a patient with no prior cardiac history shortly after starting tirzepatide.
Key Numbers
Single case; 62-year-old woman; new-onset AF with rapid ventricular response; resolved after tirzepatide discontinuation.
How They Did This
Single case report with comprehensive cardiac and metabolic workup.
Why This Research Matters
While tirzepatide is considered cardioprotective overall, clinicians should watch for rare cardiac rhythm disturbances in newly treated patients.
The Bigger Picture
As tirzepatide use expands, post-marketing surveillance for rare cardiovascular adverse events becomes increasingly important.
What This Study Doesn't Tell Us
Single case report — cannot prove causation. Temporal association does not equal causality.
Questions This Raises
- ?Is tirzepatide-associated AF dose-dependent?
- ?Should cardiac rhythm be monitored at tirzepatide initiation in susceptible patients?
Trust & Context
- Key Stat:
- No prior CVD New atrial fibrillation in a patient without cardiac history after starting tirzepatide
- Evidence Grade:
- Single case report — lowest evidence level but important for pharmacovigilance of a widely prescribed new drug.
- Study Age:
- Published in 2025, contributing to the growing post-marketing safety profile of tirzepatide.
- Original Title:
- New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report.
- Published In:
- Cureus, 17(12), e99651 (2025)
- Authors:
- Purvez, Akhtar, Mirza, Mohd, Bashir, Mudhasir
- Database ID:
- RPEP-13125
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
Can tirzepatide cause heart rhythm problems?
This is a very rare report. One patient developed atrial fibrillation after starting tirzepatide, but a causal link is not proven.
Should I worry about my heart on tirzepatide?
Tirzepatide is generally considered heart-protective. Report any palpitations or irregular heartbeat to your doctor as a precaution.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13125APA
Purvez, Akhtar; Mirza, Mohd; Bashir, Mudhasir. (2025). New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report.. Cureus, 17(12), e99651. https://doi.org/10.7759/cureus.99651
MLA
Purvez, Akhtar, et al. "New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report.." Cureus, 2025. https://doi.org/10.7759/cureus.99651
RethinkPeptides
RethinkPeptides Research Database. "New-Onset Atrial Fibrillation Potentially Associated With Ti..." RPEP-13125. Retrieved from https://rethinkpeptides.com/research/purvez-2025-newonset-atrial-fibrillation-potentially
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.